An extensive network of authorized and quality assessed partners

Central Laboratories

OPIS has efficient collaborations with GLP / GCP approved central labs across Europe and direct EDC interface with our partners for importation of laboratory data.

Phase I units

Together with qualified partners, OPIS is able to undertake a wide range of Phase I and Phase I/II type studies including pharmacokinetic and bioequivalent studies.

Investigator sites and hospitals

OPIS interacts with an expensive network of research centres across Europe and we assist Sponsors in selecting the most appropriate sites for conducting their studies.

Drug Logistics

Through the collaboration with qualified and reliable logistics partners, we can provide:

  • Clinical trials logistics
  • Customs process management
  • Project set-up
  • Drug production and stock management

Imaging Core Laboratories

High standard specialized partners provide EEC, ECG, CAT, MR and other study specific imaging for direct importation and centralized evaluation.

Non-Profit Organisations and Academic institutions

Close collaboration with a special approach. Bi-directional consultancy with universities and academics to stay on top of the latest developments in research.


Project "ITF-Becker for a new therapeutic approach to Becker muscular dystrophy", Italfarmaco SpA

RESEARCH AND INNOVATION: WHEN INDUSTRY AND HOSPITALS UNITE TO FIGHT RARE DISEASES

"ITF-Becker for a new therapeutic approach to Becker muscular dystrophy" is a project run in partnership between Italfarmaco SpA, OPIS and the Neurology, Rare Neuromuscular Diseases and Neuroradiology Units of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation. The project is among the 12 chosen in Lombardy’s "Agreements for research and innovation " (DGR n. 5245, 31 May 2016, and subsequent amendments and additions) and is backed by the 2014-2020 Lombardy regional program "Investments in favor of growth and employment".

The research funded by this agreement aims to find a new therapeutic approach to Becker muscular dystrophy, a rare disease diagnosed in only males between the age of 10 and 30 years that frequently presents osteoarticular and respiratory complications and is characterized by progressive muscular weakness leading to the loss of walking ability.

The main objective of this study is to evaluate histological improvements in muscle structure, while the secondary objectives are those of assessing effects on motor skills and magnetic resonance findings. Patients will thus undergo specific exams at the beginning of the study, during the study and after a year of treatment.

This is innovative research since few or no clinical studies are currently investigating forms of dystrophy such as Becker muscular dystrophy. This research thus represents an opportunity for many patients because it offers access to a potentially effective drug.

As a Contract Research Organization, OPIS is proud to take part in this project and to have signed this important agreement on 4/07/2017 together with the Lombardy Region, the Policlinico of Milan, and the multinational pharmaceutical company Italfarmaco as leader.

Please see the links below:

https://www.italfarmaco.com/it-it/Chi-siamo/News-ed-eventi/Dettaglio-articolo/ArticleId/40/POR-FESR-2014-2020-Linea-innovazione

https://www.italfarmaco.com/it-it/Attivit%C3%A0/Pipeline/Studi-clinici/Givinostat-per-la-Becker-ITF-BECKER

http://associazionecentrodinoferrari.com/centro-dino-ferrari-reclutamento-pazienti-affetti-da-distrofia-di-becker-per-la-nuova-sperimentazione-clinica/

http://www.policlinico.mi.it/news/2017-06-28/30/distrofia-muscolare-di-becker-firmato-un-importante-accordo-per-la-ricerca-e-l-innovazione

 

Project "ITF-Becker for a new therapeutic approach to Becker muscular dystrophy", Italfarmaco SpA